Skip to content

Difference in sensitivity to androgen response in women with different ovarian function and its prediction of IVF pregnancy outcomes (multicenter, prospective cohort study)

Difference in sensitivity to androgen response in women with different ovarian function and its prediction of IVF pregnancy outcomes (multicenter, prospective cohort study)

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088327
Enrollment
Unknown
Registered
2024-08-15
Start date
2024-08-15
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

20-34 year old group:NA
35-39 year old group:NA
40-45 year old group:NA

Sponsors

Guangdong Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) 20 years old = age =45 years old infertile women; (2) BMI 18-26; (3) AMH =0.5ng/ml and total number of AFC in both ovaries =3. (4) The first 1-3 cycles of IVF or ICSI assisted pregnancy; (5) If it is a non-first IVF/ICSI cycle, the timing of ovulation initiation must be at least one month or more from the previous cycle initiation (6) Patients and their families should know about the clinical trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Unilateral or bilateral hydrosalpinx; (2) Combined with uterine diseases: uterine malformations (single horn uterus, double horn uterus, double uterus, mediastinal uterus); Complicated with uterine adenomyosis, intrauterine adhesions, untreated endometrial polyps, submucous myoma; (3) Chromosome abnormalities in one or both spouses; (4) the male spermatogenic function is low, non-obstructive azoospermia or AZF gene microdeletion; (5) People who are allergic to ovulation stimulating drugs such as Gn; (6) There are contraindications to assisted reproductive technology or pregnancy contraindications; (7) Long-term follow-up is not possible or compliance is poor, or the investigator believes that there are any factors affecting participants' participation in the trial or evaluation of the results; (8) Ovarian granulosa cell tumor and other tumor diseases with elevated androgen

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;

Secondary

MeasureTime frame
live birth rate;Available embryo rate;Good embryo rate;Embryo implantation rate;Abortion rate;Cumulative live birth rate of one ovulation induction;

Countries

China

Contacts

Public ContactXiaomiao Zhao

Guangdong Provincial People's Hospital

zhaoxmiao@163.com+86 139 2220 9605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026